IDEAYA Biosciences, Inc. IDYA Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| External Clinical Development Expenses by Product | ||||||
| Darovasertib | $23.33M+0.3% | $23.25M-13.5% | $26.88M+7.1% | $25.09M+9.0% | $23.02M-15.4% | |
| IDE034 | $6.81M+713% | $837K— | —— | —— | $38K— | |
| IDE161 | $1.61M-10.3% | $1.79M0.0% | $1.79M+14.2% | $1.57M-35.9% | $2.45M-53.4% | |
| IDE397 | $3.52M+2.4% | $3.43M-7.2% | $3.7M-2.4% | $3.79M+1.3% | $3.74M-50.1% | |
| IDE574 | $3.05M+113% | $1.43M— | —— | —— | $643K— | |
| IDE849 | $4.77M-31.0% | $6.91M— | —— | —— | $423K-97.7% | |
| IDE892 | $2.18M-3.9% | $2.27M— | —— | —— | $860K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does IDEAYA Biosciences, Inc. break its business down?
- IDEAYA Biosciences, Inc. (IDYA) reports external clinical development expenses by product across 7 parts — Darovasertib, IDE034, IDE161, IDE397 and IDE574. Each is extracted from the segment footnotes and tracked over time.
- Where does IDEAYA Biosciences, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in IDEAYA Biosciences, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
